Form 4: Denali Therapeutics Director Steve Krognes Reports Acquisition of Equity Awards

Denali Therapeutics Inc. Director Steve E. Krognes reported the acquisition of 6,037 Restricted Stock Units and 18,111 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• Steve E. Krognes, a Director of Denali Therapeutics Inc. (DNLI), reported changes in his beneficial ownership of company securities.
• On June 3, 2025, Mr. Krognes acquired 6,037 Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of common stock each and will vest 100% upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders after the grant date.
• Additionally, Mr. Krognes acquired 18,111 stock options with an exercise price of $13.93 per share, also granted at a price of $0.
• These stock options also vest 100% under the same conditions as the RSUs: earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders after the grant date.
• Following these transactions, Mr. Krognes directly owns 31,794 shares of common stock (including 6,037 unvested RSUs) and 18,111 stock options.
• He also indirectly owns 781,797 shares of common stock through The Steve Edward Krognes Revocable Trust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an insider receiving equity compensation, which aligns their interests with shareholders. While it's a routine compensation event rather than an open market purchase, it still indicates continued commitment and confidence from a director. The dilution effect is minimal.

Positives

• The acquisition of RSUs and stock options aligns the director's interests with those of shareholders, as his compensation is tied to the company's future performance.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• The issuance of new RSUs and stock options could lead to minor dilution for existing shareholders upon vesting and exercise.

Risks

• The value of the acquired RSUs and stock options is subject to the future performance of Denali Therapeutics' stock price.

Future Outlook

The vesting conditions for the acquired RSUs and stock options indicate a forward-looking compensation structure designed to incentivize the director's continued contribution to the company's long-term success, with vesting tied to future anniversaries or the next annual meeting.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation in the biotechnology industry, where equity-based awards like RSUs and stock options are common tools to attract, retain, and incentivize key personnel, aligning their financial interests with company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential minor dilution from the vesting and exercise of new equity awards, but also increased alignment of a director's interests with shareholder value.
• Management/Employees: Reinforces the company's compensation strategy to retain and incentivize key leadership.

Next Steps

• The acquired Restricted Stock Units and stock options will vest according to their specified schedules, either on the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders, whichever is earlier.
• Mr. Krognes will continue to hold his beneficial ownership in Denali Therapeutics Inc. as reported.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals